CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTERESTS AND SHAREHOLDERS' EQUITY - USD ($) $ in Millions	Total	Redeemable Noncontrolling Interests	Common Stock	Treasury Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive (Loss) Income	Total Shareholders' Equity Attributable to Bruker Corporation	Noncontrolling Interests in Consolidated Subsidiaries
Balance at beginning of period at Dec. 31, 2021	$ 1,084.6	$ 0.2	$ 1.7	$ (820.3)	$ 237.8	$ 1,659.5	$ (8.2)	$ 1,070.5	$ 14.1
Balance (in shares) at Dec. 31, 2021			150,753,687	24,151,348
Increase (Decrease) in Stockholders' Equity
Stock options exercised	5.8				5.8			5.8
Stock options exercised (in shares)			251,006
Restricted stock units vested	(3.0)				(3.0)			(3.0)
Restricted stock units vested (in shares)			233,545
Stock based compensation	15.7				15.7			15.7
Shares repurchased	(264.7)			$ (264.7)				(264.7)
Shares repurchased (in shares)			(4,215,094)	4,215,094
Cash dividends paid to common shareholders	(29.8)					(29.8)		(29.8)
Other shareholders of majority-owned acquisitions		6.8
Distributions to noncontrolling interests	(1.2)								(1.2)
Consolidated net income	299.1	(0.6)				296.6		296.6	2.5
Acquisition of minority interest	(3.1)					(0.3)	(0.2)	(0.5)	(2.6)
Other comprehensive (loss)	22.3	(0.3)					23.2	23.2	(0.9)
Balance at end of period at Dec. 31, 2022	1,125.7	6.1	$ 1.7	$ (1,085.0)	256.3	1,926.0	14.8	1,113.8	11.9
Balance (in shares) at Dec. 31, 2022			147,023,144	28,366,442
Increase (Decrease) in Stockholders' Equity
Stock options exercised	9.7				9.7			9.7
Stock options exercised (in shares)			285,030
Restricted stock units vested	(3.4)				(3.4)			(3.4)
Restricted stock units vested (in shares)			215,959
Stock based compensation	17.6	0.1			17.6			17.6
Shares repurchased	(153.4)			$ (152.2)	(1.2)			(153.4)
Shares repurchased (in shares)			(2,412,437)	2,412,437
Employee stock purchase plan	3.9				3.9			3.9
Employee stock purchase plan (in shares)			53,130
Cash dividends paid to common shareholders	(29.4)					(29.4)		(29.4)
Proceeds from the sale of non-controlling interests, net of loan receivable of $0.3	5.0								5.0
Other shareholders of majority-owned acquisitions		12.6
Distributions to noncontrolling interests	(2.0)								(2.0)
Consolidated net income	429.2	(0.7)				427.2		427.2	2.0
Other comprehensive (loss)	(8.3)	0.6					(8.8)	(8.8)	0.5
Balance at end of period at Dec. 31, 2023	1,394.6	18.7	$ 1.7	$ (1,237.2)	282.9	2,323.8	6.0	1,377.2	17.4
Balance (in shares) at Dec. 31, 2023			145,164,826	30,778,879
Increase (Decrease) in Stockholders' Equity
Stock options exercised	4.6				4.6			4.6
Stock options exercised (in shares)			208,700
Restricted stock units vested	(3.3)				(3.3)			(3.3)
Restricted stock units vested (in shares)			217,576
Stock based compensation	20.3	0.1			20.3			20.3
Employee stock purchase plan	6.0				6.0			6.0
Employee stock purchase plan (in shares)			86,850
Public Offering, net of issuance costs	403.0		$ 0.1		402.9			403.0
Public Offering, net of issuance costs (in shares)			6,000,000
Cash dividends paid to common shareholders	(30.2)					(30.2)		(30.2)
Loans to noncontrolling interest	(0.8)								(0.8)
Consolidated net income	113.5	0.3				113.1		113.1	0.4
Other comprehensive (loss)	(110.6)	(1.0)					(109.5)	(109.5)	(1.1)
Balance at end of period at Dec. 31, 2024	$ 1,797.1	$ 18.1	$ 1.8	$ (1,237.2)	$ 713.4	$ 2,406.7	$ (103.5)	$ 1,781.2	$ 15.9
Balance (in shares) at Dec. 31, 2024			151,677,952	30,778,879